Summary
Fortress Biotech is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products.
Company assets include interests in ten biotech companies, three of which are publicly listed, a publicly listed, full-service investment bank, and a special purpose acquisition company ("SPAC").
Since five portfolio companies are publicly listed, we can calculate the value of its public portfolio, which in return allows us to calculate the market-implied value of the private portfolio.
The private portfolio, however, appears to be undervalued given the expectable market capitalization of the IPO of subsidiary Caelum Biosciences.
I would like to present you with my analysis of a company that I've been intrigued by ever since it came up on one of my biotech stock screeners, because it is truly unlike anything else you can find in the public biotech markets.
It is not one, but ten biotech companies bundled into one, with a very broad pipeline of drugs, ranging from pre-clinical to late-stage. It also includes interests in a full-service investment bank and a special purpose acquisition company ("SPAC"). While a majority of its subsidiaries are still private and offer limited financial information, we can easily assess the value of its public portfolio, and use it to make an estimate of the private portfolio's value. To the benefit of an investor, the company does not only offer catalysts through its pipeline, but also through the planned initial public offering of a subsidiary in the next months. This highly intriguing company is called Fortress Biotech (NASDAQ:FBIO).

